Pharmaceutical Drug Delivery Market Size, Share & Trends

7500+ companies worldwide approach us every year for their revenue growth initiatives
Global top 2000 strategist rely on us for their growth strategies.
80% of fortune 2000 companies rely on our research to identify new revenue sources.
30000 High Growth Opportunities
95% renewal rate
KNOW MORE
  1. HOME
  2. Top Market Reports
  3. Pharmaceutical Drug Delivery Market

Pharmaceutical Drug Delivery Market by Route of Administration [Oral, Injectors (Pen, Auto Injectors) Implantable, Syrups, Gels, Pulmonary, Tablets, Syringes], Application (Cancer, Diabetes), Facility of Use (Hospital, Home Care) -Global Forecast to 2029

FREE BROCHURE FREE SAMPLE REPORT
Report Code: MD 3871 Sep, 2024, by marketsandmarkets.com

The global pharmaceutical drug delivery market is projected to reach USD 2,546.0 billion by 2029 from USD 1,949.4 billion in 2024 at a CAGR of 5.5 % during the forecast period. The rising global incidence of chronic diseases, the launch of new products, increased investment in pharmaceutical R&D, the emphasis on patient comfort & compliance, and government initiatives to provide affordable drug delivery products are some factors driving market growth. Other factors include the growing geriatric population and rising cases of diabetes, hypertension, cancer, and infectious diseases. The market has also shown trends such as the modernization of drug delivery technology, the patient preference for home-based care, supportive reimbursement policies, and government-backed healthcare development, which would support the growth of hospitals and ambulatory diagnostic centers, improving access to pharmacological therapies among patients.

Exciting Opportunities in the Pharmaceutical Drug Delivery Market

Pharmaceutical Drug Delivery Market

To know about the assumptions considered for the study, Request for Free Sample Report

Pharmaceutical Drug Delivery Market

Pharmaceutical Drug Delivery Market Dynamics

Driver: Rising prevalence of chronic diseases

The growing number of people suffering from chronic illnesses worldwide is likely to propel the growth of the pharmaceutical delivery market significantly. Since these diseases are mainly associated with age, with the rising geriatric population, the incidences of diabetes mellitus type 2 and high blood pressure have gone up. The WHO predicts that, by 2025, most deaths shall arise from chronic diseases, accounting for 73%, while they account for about 60% of the global burden of diseases. Additionally, according to the WHO, the world’s population of people aged 60 years and older will double by 2050. As the elderly are more susceptible to chronic diseases, the growth of this population segment will push the demand for better public health systems and medical treatments. As the prevalence of several chronic diseases progresses across the globe, the demand for effective and advanced drug-delivery technologies is expected to rise.

Restraint: Risk of needlestick injuries

Injectable drug delivery comes with the risk of needlestick injuries. The increasing prevalence of these injuries and subsequent infections from contaminated needles is a major global concern, posing severe health and safety threats to healthcare workers as well as the patient population. Reports have shown that there are more than two million occupational needlestick injuries each year, according to European Pharmaceutical Manufacturer, in 2023, even with the extensive safety measures taken. In 2022, the WHO categorized needlestick injuries as 36.7% resulting in hepatitis B, 39% hepatitis C, and 4.4% HIV/AIDS among medical practitioners globally. Given its adverse effects on patients and caretakers alike, the demand for injectable drugs may be influenced within this context.

Opportunity: Increased acceptance of self-administration and home care

The drug delivery market for pharmaceutical products will likely experience substantial growth due to self-administration and home care trends. This shift seems to be mainly driven by the rising geriatric population, a major consumer of drug delivery devices in home care settings. Self-administration allows patients to take more responsibility for managing their health, making them feel more in control over their lives and improving their overall quality of life. Therefore, single-use medication devices could significantly improve adherence to prescribed medications and give rise to positive treatment outcomes.

Challenge: Government Pricing pressure

To increase affordability, governments and regulatory bodies impose price caps on medicines, thus limiting the revenue potential for pharmaceutical companies.

Government agencies, insurers, and patients are putting tremendous pressure on drug makers worldwide to reduce costs. Insurance companies bargain for reduced drug costs to cover expenses. This lowers the revenue received by pharmaceutical companies, hence controlling their profit margins. Because of the decreased pricing pressure, pharmaceuticals are being adopted more widely in emerging economies with a large need for affordable therapies. Still, this has affected the bottom line for many pharmaceutical companies. Because of ongoing pressure from insurers, pharmacy benefit managers (PBMs), and public and private payers to lower pharmaceutical prices due to worries about paying for more new medications, this pattern is anticipated to continue in the years ahead.

Each country has a very different structure for patient price sensitivity when it comes to local rules. Certain nations, including Japan, have legislative frameworks that offer doctors financial rewards for prescribing particular treatments. However, by implementing physician budgets for prescriptions, several European markets deter doctors from prescribing expensive medicines.

Pharmaceutical Drug Delivery Market Landscape

The pharmaceutical drug delivery market focuses on technologies for efficiently administering medications. Key players include pharmaceutical companies, biotech firms, and device manufacturers. Route of administration range from oral and injectable systems to advanced methods like autoinjectors used for various therapeutic areas. End users are healthcare providers, patients, research labs, and homecare settings. The market is driven by innovation, regulatory challenges, and a shift towards personalized medicine.

Pharmaceutical Drug Delivery Market Ecosystem

Injectable drug delivery will capture the largest share of the pharmaceutical drug delivery market

Based on the route of administration, the injectable drug delivery market is set to be the largest segment in the pharmaceutical drug delivery market. As chronic diseases become more common, injectables have become a go-to solution for managing a variety of conditions. Injections provide a solution to hormonal imbalances, cancer, autoimmune disorders, or rare diseases in which oral medication may not work effectively.

One major benefit of injectables is their ability to simplify treatment regimens. These drugs reduce patients’ daily intake, enhancing their medication adherence and maintaining the treatment efficacy. Pharmaceutical companies are focusing on improving the delivery and packaging of these injectables to make them more efficient and user-friendly. With a growing trend towards self-administration and home care, there have been impressive advancements in the technology behind syringes, cartridges, autoinjectors, and pen injectors. These innovations, including better needle designs and more comfortable devices, have made injections less intimidating and less painful, which is contributing to the rapid growth of this market.

Hospitals to show significant growth in the pharmaceutical drug delivery market, by facility of use

Based on the facility of use, it is estimated that hospitals will expand significantly due to ease of access. Due to a high number of patients visiting them on both an inpatient or outpatient basis and the need for high amounts of medication and their usage devices, the hospitals segment is expected to experience significant growth. Technological advancements, such as smart pumps and automated infusion devices, are improving the precision and reliability of drug delivery. Increased hospitalization rates and a heightened focus on patient safety and adherence to treatment protocols further drive the need for sophisticated delivery solutions. In addition, this segment has been further influenced by increased surgical cases and rising incidences of chronic diseases globally, leading to an increase in the number of patients admitted, thus accelerating the pharmaceutical drug delivery market growth within this area.

North America to account for the largest share during the forecast period.

Pharmaceutical Drug Delivery Market by Region

To know about the assumptions considered for the study, download the pdf brochure

North America is anticipated to represent the largest regional market during the forecast period. The regional market, comprising the US and Canada, shows high demand for drug delivery technologies. This is mainly due to the availability of favorable reimbursement options, growing awareness of new technologies, favorable government initiatives, the growing affordability & per capita healthcare expenditure, the presence of many global pharmaceutical giants (such as Pfizer and Johnson & Johnson), and the patent expiry of blockbuster drugs during 2019–2025.

As of 2023, prominent players in the global pharmaceutical drug delivery market include Johnson & Johnson Services (US) , Novartis AG (Switzerland), F. Hoffmann-La Roche (Switzerland), Pfizer (US), Becton, Dickinson and Company (US), GlaxoSmithKline (UK) Merck & Co. (US) , Sanofi (France) , Bayer AG (Germany) , Amgen (US) , AbbVie (US) , Genmab A/S (Denmark) , Gilead Sciences (US), Boehringer Ingelheim International (Germany) , and AstraZeneca (UK) .

Scope of the Pharmaceutical Drug Delivery Market Report

Report Metric

Details

Market size available for years

2022–2029

Base year considered

2023

Forecast period

2024–2029

Forecast units

Value (USD Million/Billion)

Segments covered

Route of administration, application, facility of use, and region

Geographies covered

North America, Europe, Asia Pacific, Latin America, and Middle East & Africa

This research report categorizes the pharmaceutical drug delivery market based on route of administration, application, facility of use, and region.

By Route Of Administration
  • Oral Drug Delivery
    • Solid Oral Drug Formulation
      • Tablets
      • Capsules
      • Oral Powders
      • Oral Pills
    • Liquid Oral Drug Formulation
      • Oral Syrups
      • Oral Solutions
      • Oral Emulsions
      • Oral Elixirs
    • Semi Semi-solid oral Drug Formulation
      • Oral Gels
      • Oral Paste
  • Injectable Drug Delivery
    • By Device
      • Conventional Injection Devices
    • By Material
      • Glass
      • Plastic
    • By Product
      • Fillable Syringes
      • Prefilled Syringes
    • By Usability
      • Reusable Syringes
      • Disposable Syringes
  • Self Injection Devices
    • Needle-Free Injectors
    • Autoinjectors
    • Pen Injectors
    • Wearable Injectors
  • Other Injection Devices
  • Topical & Trandermal Drug Delivery
    • Liquid Topical Drug Ormulations
      • Solutions
      • Suspensions
      • Emulsions
    • Solid Topical Drug Formulations
      • Suppositories
      • Powders
    • Semi-Solid Topical Drug Formulations
      • Creams
      • Gels
      • Ointments
      • Pastes
      • Lotions
    • Transdermal Drug Formulation
      • Transdermal Patches
      • Transdermal Gels
      • Transdermal Sprays
  • Ocular Drug Delivery
    • Liquid Occular Drug Formulations
      • Eye Drops
      • Liquid Sprays
    • Semi-Solid Ocular Drug Formulations
      • Gels
      • Eye Ointments
    • Ocular Devices
      • Drug Coated Contact Lenses
      • Ocular Inserts
  • Pulmonary Drug Delivery
    • Meterd Dose Inhalers 
    • Dry Powder Inhalers 
    • Nebulizers
      • Jet Nebulizers
      • Ultrasonic Nebulizers
      • Soft Mist Nebulizers
  • Nasal Drug Delivery
    • Nasal Drops 
    • Nasal Sprays 
    • Nasal Powders
    • Nasal Gels
  • Transmucosal Drug Delivery
    • Oral Transmucosal Formulations
      • Buccal Drug Delivery
      • Sublingual Drug Delivery
    • Other Transmucosal Drug Delivery Technologies
      • Rectal Transmucosal Drug Delivery
      • Vaginal Transmucosal Drug Delivery
  • Implantable Drug Delivery
    • Active Implantable Drug Delivery
    • Passive Implantable Drug Delivery
By Facility Of Use
  • Hospitals
  • Ambulatory Surgical Centers/Clinics
  • Home Care Settings
  • Diagnostic Centers
  • Other Facilities Of Use (Reserch Institutes, Cros)
By Application
  • Infectious Disease
  • Cancer
  • Cardiovascular Disease
  • Diabetes
  • Respiratory Disease
  • Autoimmune Diseases
  • Central Nervous System Disorders
  • Other Applications (Endocrine Diseases, Pain Management, Opthalmic Disorders, Amoung Others ) 
By Region
  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • RoEU
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • RoAPAC
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC Countries
    • Rest of the Middle East & Africa

Recent Advancements in the Pharmaceutical Drug Delivery Market

  • In March 2024, Johnson & Johnson acquired Ambrx Biopharma. This will strengthen J&J’s commitment to innovation in prostate cancer therapies and deepen the pipeline of next-generation antibody-drug conjugates and targeted oncologic therapeutics.
  • In January 2024, AbbVie expanded its biologics manufacturing capacity at its Singapore manufacturing site with an investment of USD 223 million.
  • In June 2023, GSK acquired BELLUS Health. The acquisition provided access to Camlipixant, a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with refractory chronic cough.
  • In June 2023, Merck acquired Prometheus Biosciences. The acquisition will deliver industry-leading research capability and strengthen the pipeline with a novel candidate for ulcerative colitis, Crohn’s disease, and other autoimmune conditions.
  • In October 2022, Pfizer acquired Biohaven Pharmaceutical Holding Company Ltd., which added a breakthrough portfolio, including Nurtec ODT (Rimegepant), an innovative migraine therapy, to Pfizer’s offerings.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION 
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
 
4 PREMIUM INSIGHTS (Page No. - 76)
    4.1 PHARMACEUTICAL DRUG DELIVERY MARKET OVERVIEW 
    4.2 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE AND COUNTRY 
    4.3 PHARMACEUTICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
 
5 MARKET OVERVIEW (Page No. - 79)
    5.1 MARKET DYNAMICS 
           5.1.1 DRIVERS
                    5.1.1.1 Rising prevalence of chronic diseases
                    5.1.1.2 Technological advancements and product launches
                    5.1.1.3 Rising investments in pharmaceutical R&D
                    5.1.1.4 Growing emphasis on patient convenience
                    5.1.1.5 Government initiatives to boost affordability
           5.1.2 RESTRAINTS
                    5.1.2.1 High development costs
           5.1.3 OPPORTUNITIES
                    5.1.3.1 Increased preference for self-administration and home care
                    5.1.3.2 Rising interest in biosimilars and biologics
                    5.1.3.3 Market opportunities in emerging economies
                    5.1.3.4 Development of biocompatible materials for drug delivery systems
           5.1.4 CHALLENGES
                    5.1.4.1 Pricing pressure from governing bodies
                    5.1.4.2 Risk of needlestick injuries
    5.2 REGULATORY LANDSCAPE 
           5.2.1 NORTH AMERICA
                    5.2.1.1 US
                    5.2.1.2 Canada
           5.2.2 EUROPE
                    5.2.2.1 Germany
                    5.2.2.2 Italy
                    5.2.2.3 France
                    5.2.2.4 UK
                    5.2.2.5 Switzerland
           5.2.3 ASIA PACIFIC
                    5.2.3.1 China
                    5.2.3.2 Japan
                    5.2.3.3 India
                    5.2.3.4 South Korea
                    5.2.3.5 Australia
           5.2.4 LATIN AMERICA
           5.2.5 MIDDLE EAST & AFRICA
           5.2.6 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.3 VALUE CHAIN ANALYSIS 
    5.4 SUPPLY CHAIN ANALYSIS 
           5.4.1 PROMINENT COMPANIES
           5.4.2 SMALL & MEDIUM-SIZED COMPANIES
           5.4.3 END USERS
    5.5 ECOSYSTEM ANALYSIS 
    5.6 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
    5.7 TECHNOLOGY ANALYSIS 
           5.7.1 KEY TECHNOLOGIES
           5.7.2 AUTOMATED INSULIN DELIVERY (AID)
                    5.7.2.1 Wearable patches
                    5.7.2.2 On-body drug delivery systems
                    5.7.2.3 Needle-free drug delivery systems
                    5.7.2.4 3D printing
                    5.7.2.5 Responsive hydrogels
                    5.7.2.6 Exosomes and extracellular vesicles
                    5.7.2.7 Polymeric particles and implants
                    5.7.2.8 Atomic layer deposition
                    5.7.2.9 Ingestible injectables
                    5.7.2.10 Ocular drug delivery
           5.7.3 COMPLEMENTARY TECHNOLOGIES
                    5.7.3.1 Pen injectors
                    5.7.3.2 Prefilled syringes
                    5.7.3.3 Autoinjector technology
                    5.7.3.4 Nanotechnology
    5.8 TRADE ANALYSIS 
           5.8.1 TRADE ANALYSIS FOR SYRINGES, WITH OR WITHOUT NEEDLES, USED IN MEDICAL, SURGICAL, DENTAL, OR VETERINARY SCIENCES
           5.8.2 TRADE ANALYSIS FOR MEDICAMENTS IN MEASURED DOSES, INCLUDING TRANSDERMAL ADMINISTRATION
    5.9 PATENT ANALYSIS 
           5.9.1 PATENT PUBLICATION TRENDS FOR PHARMACEUTICAL DRUG DELIVERY TECHNOLOGIES
           5.9.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
    5.10 PORTER’S FIVE FORCES ANALYSIS 
           5.10.1 THREAT OF NEW ENTRANTS
           5.10.2 THREAT OF SUBSTITUTES
           5.10.3 BARGAINING POWER OF SUPPLIERS
           5.10.4 BARGAINING POWER OF BUYERS
           5.10.5 INTENSITY OF COMPETITIVE RIVALRY
    5.11 KEY STAKEHOLDERS & BUYING CRITERIA 
           5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
           5.11.2 BUYING CRITERIA
    5.12 PRICING ANALYSIS 
    5.13 KEY CONFERENCES & EVENTS (2024–2025) 
    5.14 REIMBURSEMENT ANALYSIS 
    5.15 CASE STUDY ANALYSIS 
    5.16 INVESTMENT & FUNDING SCENARIO 
    5.17 UNMET NEEDS IN PHARMACEUTICAL DRUG DELIVERY MARKET 
    5.18 END-USER EXPECTATIONS IN PHARMACEUTICAL DRUG DELIVERY MARKET 
    5.19 AI INTEGRATION IN PHARMACEUTICAL DRUG DELIVERY MARKET 
 
6 PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION (Page No. - 123)
    6.1 INTRODUCTION 
    6.2 INJECTABLE DRUG DELIVERY 
           6.2.1 CONVENTIONAL INJECTION DEVICES
                    6.2.1.1 Conventional injection devices market, by material
                               6.2.1.1.1 Glass syringes
                                             6.2.1.1.1.1 Durability and safety to drive adoption
                               6.2.1.1.2 Plastic syringes
                                             6.2.1.1.2.1 Lower price compared to glass syringes to propel adoption
                    6.2.1.2 Conventional injection devices market, by product
                               6.2.1.2.1 Fillable syringes
                                             6.2.1.2.1.1 Ease of use and variable dosing formulations of fillable syringes to drive market
                               6.2.1.2.2 Prefilled syringes
                                             6.2.1.2.2.1 Improved dose accuracy and increased patient convenience & safety to support usage
                    6.2.1.3 Conventional injection devices market, by usability
                               6.2.1.3.1 Reusable syringes
                                             6.2.1.3.1.1 Ease of use, dismantling, and cleaning to support market growth
                               6.2.1.3.2 Disposable syringes
                                             6.2.1.3.2.1 Low cost and convenience to favor end-user demand
           6.2.2 SELF-INJECTION DEVICES
                    6.2.2.1 Needle-free injectors
                               6.2.2.1.1 Rapid drug delivery and better reproducibility than invasive drug delivery systems to support market growth
                    6.2.2.2 Autoinjectors
                               6.2.2.2.1 Improved patient satisfaction compared to manual injections to drive market
                    6.2.2.3 Pen injectors
                               6.2.2.3.1 Need for multi-dose devices to propel adoption
                    6.2.2.4 Wearable injectors
                               6.2.2.4.1 Increasing adoption of home infusion therapy and rising focus on cost-curtailment in healthcare to support market growth
    6.3 ORAL DRUG DELIVERY 
           6.3.1 SOLID ORAL DRUGS
                    6.3.1.1 Tablets
                               6.3.1.1.1 Development of mini-tablets to propel market growth
                    6.3.1.2 Capsules
                               6.3.1.2.1 Easy absorption of drugs and decreased irritation in GI tract drive capsule usage
                    6.3.1.3 Oral powders
                               6.3.1.3.1 Convenience for patients with trouble swallowing other dosage forms to propel usage
                    6.3.1.4 Pills
                               6.3.1.4.1 Rising incidence of target ailments to propel market growth
           6.3.2 LIQUID ORAL DRUGS
                    6.3.2.1 Oral syrups
                               6.3.2.1.1 Ease of administration to drive usage
                    6.3.2.2 Oral solutions
                               6.3.2.2.1 Rising preference among geriatric and pediatric patients to support adoption
                    6.3.2.3 Oral emulsions
                               6.3.2.3.1 Enhanced solubility, stability, and ease of administration to drive market
                    6.3.2.4 Oral elixirs
                               6.3.2.4.1 Rising preference in pediatric cases to drive market
           6.3.3 SEMI-SOLID ORAL DRUGS
                    6.3.3.1 Oral gels
                               6.3.3.1.1 Controlled drug release benefits to propel usage
                    6.3.3.2 Oral pastes
                               6.3.3.2.1 Protection against oxidation and enzymatic hydrolysis to support adoption
    6.4 TOPICAL DRUG DELIVERY 
           6.4.1 SEMI-SOLID TOPICAL FORMULATIONS
                    6.4.1.1 Topical creams
                               6.4.1.1.1 Variable efficacy to affect end-user adoption
                    6.4.1.2 Topical gels
                               6.4.1.2.1 Faster drug release and greater patient acceptability to drive the market for topical gels
                    6.4.1.3 Topical ointments
                               6.4.1.3.1 Wide usage in analgesic indications to drive market
                    6.4.1.4 Topical pastes
                               6.4.1.4.1 Wide usage in treating/preventing skin irritation to support growth
                    6.4.1.5 Topical lotions
                               6.4.1.5.1 Ease of administration of lotions to drive demand
           6.4.2 LIQUID TOPICAL FORMULATIONS
                    6.4.2.1 Topical suspensions
                               6.4.2.1.1 High bioavailability and controlled onset of action to support adoption
                    6.4.2.2 Topical emulsions
                               6.4.2.2.1 Improved spreadability, stability, and controlled release of active ingredients
                    6.4.2.3 Topical solutions
                               6.4.2.3.1 Ease of use and ready availability to support market growth
           6.4.3 SOLID TOPICAL FORMULATIONS
                    6.4.3.1 Topical powders
                               6.4.3.1.1 Rising incidence of skin disorders to drive market
                    6.4.3.2 Suppositories
                               6.4.3.2.1 Compatibility and stability to support growth
           6.4.4 TRANSDERMAL PRODUCTS
                    6.4.4.1 Transdermal patches
                               6.4.4.1.1 Prevention of premature metabolization of drugs to drive market
                    6.4.4.2 Transdermal gels
                               6.4.4.2.1 Rapid drug release capabilities to support usage of gels
                    6.4.4.3 Transdermal sprays
                               6.4.4.3.1 Simplicity and noninvasive nature to support adoption
    6.5 OCULAR DRUG DELIVERY 
           6.5.1 LIQUID OCULAR FORMULATIONS
                    6.5.1.1 Eye drops
                               6.5.1.1.1 Rising prevalence of cataracts and other eye diseases to drive market growth
                    6.5.1.2 Liquid ocular sprays
                               6.5.1.2.1 Benefits over eye drops to support market growth
           6.5.2 SEMI-SOLID OCULAR FORMULATIONS
                    6.5.2.1 Ocular gels
                               6.5.2.1.1 High viscosity, prolonged drug release, and ease of drug administration to support market growth
                    6.5.2.2 Eye ointments
                               6.5.2.2.1 Safety and efficient administration to drive market
           6.5.3 OCULAR DEVICES
                    6.5.3.1 Ocular inserts
                               6.5.3.1.1 Support for sustained drug release to drive adoption
                    6.5.3.2 Drug-coated contact lenses
                               6.5.3.2.1 Better eyesight offered by lenses and high compliance to drive market
    6.6 PULMONARY DRUG DELIVERY 
           6.6.1 METERED-DOSE INHALERS
                    6.6.1.1 Support for coordinating inhaler actuation and patient breath to drive adoption
           6.6.2 DRY POWDER INHALERS
                    6.6.2.1 Chemical stability of formulations to support usage
           6.6.3 NEBULIZERS
                    6.6.3.1 Jet nebulizers
                               6.6.3.1.1 Jet nebulizers to account for largest share of nebulizers market
                    6.6.3.2 Ultrasonic nebulizers
                               6.6.3.2.1 Ease of use and comfort for patients to propel adoption
                    6.6.3.3 Soft mist nebulizers
                               6.6.3.3.1 Rising preference in COPD treatment to propel market
    6.7 NASAL DRUG DELIVERY 
           6.7.1 NASAL SPRAYS
                    6.7.1.1 Applications in relieving nasal congestion, runny nose, itchy nose, and sneezing to support adoption
           6.7.2 NASAL DROPS
                    6.7.2.1 Efficiency over nasal sprays to drive adoption
           6.7.3 NASAL GELS
                    6.7.3.1 Long-lasting relief and reduced irritation to support growth
           6.7.4 NASAL POWDERS
                    6.7.4.1 Absence of preservatives and stability of formulations to support adoption
    6.8 TRANSMUCOSAL DRUG DELIVERY 
           6.8.1 ORAL TRANSMUCOSAL FORMULATIONS
           6.8.2 BUCCAL DRUG DELIVERY
                    6.8.2.1 Applications in local and systematic therapies to drive adoption
                    6.8.2.2 Sublingual drug delivery
                               6.8.2.2.1 High rate of adoption to propel usage
           6.8.3 OTHER TRANSMUCOSAL FORMULATIONS
                    6.8.3.1 Rectal drug delivery
                               6.8.3.1.1 High vascularization to support rapid drug absorption
                    6.8.3.2 Vaginal drug delivery
                               6.8.3.2.1 Higher permeability and drug stability to drive market
    6.9 IMPLANTABLE DRUG DELIVERY 
           6.9.1 PASSIVE IMPLANTABLE DRUG DELIVERY
                    6.9.1.1 Targeted drug delivery benefits to propel market
           6.9.2 ACTIVE IMPLANTABLE DRUG DELIVERY
                    6.9.2.1 Need for better diagnostic monitoring and body fluid transportation to favor market growth
 
7 PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION (Page No. - 260)
    7.1 INTRODUCTION 
    7.2 INFECTIOUS DISEASES 
           7.2.1 HIGH BURDEN OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
    7.3 CANCER 
           7.3.1 GROWING INCIDENCE OF CANCER TO ENSURE DEMAND FOR THERAPY
    7.4 CVD 
           7.4.1 INCREASING PREVALENCE AND INCREASING INNOVATION IN DRUG DELIVERY TECHNOLOGIES TO PROPEL MARKET GROWTH
    7.5 DIABETES 
           7.5.1 EMERGENCE OF NEW TECHNOLOGIES TO SUPPORT MARKET GROWTH
    7.6 RESPIRATORY DISEASES 
           7.6.1 HIGH PREVALENCE OF ASTHMA AND COPD TO DRIVE ADOPTION OF PHARMACEUTICAL DRUG DELIVERY TECHNOLOGIES
    7.7 CNS DISORDERS 
           7.7.1 WIDE USAGE OF ORAL AND INJECTABLE DRUG DELIVERY SYSTEMS TO DRIVE MARKET
    7.8 AUTOIMMUNE DISEASES 
           7.8.1 AUTOIMMUNE DISEASES TO REGISTER HIGHEST GROWTH
    7.9 OTHER APPLICATIONS 
           7.9.1 OPHTHALMIC DISORDERS
           7.9.2 ENDOCRINE DISORDERS
 
8 PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE (Page No. - 278)
    8.1 INTRODUCTION 
    8.2 HOSPITALS 
           8.2.1 HOSPITALS TO HOLD LARGEST MARKET SHARE THROUGHOUT FORECAST PERIOD
    8.3 AMBULATORY SURGERY CENTERS/CLINICS 
           8.3.1 INCREASING PREFERENCE FOR AMBULATORY CARE TO FUEL DEMAND FOR PHARMACEUTICAL DRUG DELIVERY TECHNOLOGIES
    8.4 HOME CARE SETTINGS 
           8.4.1 HOME CARE SETTINGS TO REGISTER HIGHEST GROWTH RATE
    8.5 DIAGNOSTIC CENTERS 
           8.5.1 RISING PREVALENCE OF CHRONIC DISEASES TO SUPPORT MARKET GROWTH
    8.6 OTHER FACILITIES OF USE 
 
9 PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION (Page No. - 289)
    9.1 INTRODUCTION 
    9.2 NORTH AMERICA 
           9.2.1 US
                    9.2.1.1 US to dominate North American pharmaceutical drug delivery market
           9.2.2 CANADA
                    9.2.2.1 Government support for research and rising prevalence of chronic diseases to drive market
    9.3 EUROPE 
           9.3.1 GERMANY
                    9.3.1.1 Growing focus of pharmaceutical companies on developing innovative drug delivery products to drive market
           9.3.2 FRANCE
                    9.3.2.1 Presence of leading pharmaceutical companies and rising prevalence of chronic diseases to drive market
           9.3.3 ITALY
                    9.3.3.1 Increasing focus on clinical research and growing popularity of branded drugs to drive demand
           9.3.4 UK
                    9.3.4.1 Increasing incidence and prevalence of chronic and infectious diseases to drive market
           9.3.5 SPAIN
                    9.3.5.1 Increase in biologics production to support market growth
           9.3.6 REST OF EUROPE
    9.4 ASIA PACIFIC 
           9.4.1 CHINA
                    9.4.1.1 High diabetes incidence and favorable government initiatives to drive market
           9.4.2 JAPAN
                    9.4.2.1 Favorable government initiatives and increased geriatric population to drive market growth in Japan
           9.4.3 INDIA
                    9.4.3.1 Growing generic demand and rising government initiatives to drive market
           9.4.4 AUSTRALIA
                    9.4.4.1 Favorable government initiatives and outlook for pharma sector to support growth
           9.4.5 SOUTH KOREA
                    9.4.5.1 Growing pharmaceutical segment to support demand for delivery technologies
           9.4.6 REST OF ASIA PACIFIC
    9.5 LATIN AMERICA 
           9.5.1 BRAZIL
                    9.5.1.1 Investments and government support to attract multinational pharma companies to Brazil
           9.5.2 MEXICO
                    9.5.2.1 Growth and diversification in Mexico’s pharmaceutical exports to drive market
           9.5.3 REST OF LATIN AMERICA
    9.6 MIDDLE EAST & AFRICA 
           9.6.1 GCC COUNTRIES
                    9.6.1.1 Rising healthcare expenditure to drive market growth
           9.6.2 REST OF MIDDLE EAST & AFRICA
 
10 COMPETITIVE LANDSCAPE (Page No. - 557)
     10.1 OVERVIEW 
     10.2 KEY PLAYER STRATEGY/RIGHT TO WIN 
             10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN PHARMACEUTICAL DRUG DELIVERY MARKET
     10.3 REVENUE ANALYSIS 
     10.4 MARKET SHARE ANALYSIS 
     10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 
             10.5.1 STARS
             10.5.2 EMERGING LEADERS
             10.5.3 PERVASIVE PLAYERS
             10.5.4 PARTICIPANTS
             10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
                        10.5.5.1 Company footprint
                        10.5.5.2 Route of administration footprint
                        10.5.5.3 Region footprint
     10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 
             10.6.1 PROGRESSIVE COMPANIES
             10.6.2 RESPONSIVE COMPANIES
             10.6.3 DYNAMIC COMPANIES
             10.6.4 STARTING BLOCKS
             10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
     10.7 VALUATION & FINANCIAL METRICS 
             10.7.1 FINANCIAL METRICS
             10.7.2 COMPANY VALUATION
     10.8 BRAND/PRODUCT COMPARISON 
     10.9 COMPETITIVE SCENARIO 
             10.9.1 PRODUCT LAUNCHES & APPROVALS
             10.9.2 DEALS
             10.9.3 EXPANSIONS
             10.9.4 OTHER DEVELOPMENTS
 
11 COMPANY PROFILES (Page No. - 574)
     11.1 KEY PLAYERS 
             11.1.1 JOHNSON & JOHNSON SERVICES, INC.
                        11.1.1.1 Business overview
                        11.1.1.2 Products offered
                        11.1.1.3 Recent developments
                                     11.1.1.3.1 Product approvals
                                     11.1.1.3.2 Deals
                                     11.1.1.3.3 Other developments
                        11.1.1.4 MnM view
                                     11.1.1.4.1 Right to win
                                     11.1.1.4.2 Strategic choices
                                     11.1.1.4.3 Weaknesses and competitive threats
             11.1.2 NOVARTIS AG
                        11.1.2.1 Business overview
                        11.1.2.2 Products offered
                        11.1.2.3 Recent developments
                                     11.1.2.3.1 Product approvals
                                     11.1.2.3.2 Deals
                        11.1.2.4 MnM view
                                     11.1.2.4.1 Right to win
                                     11.1.2.4.2 Strategic choices
                                     11.1.2.4.3 Weaknesses and competitive threats
             11.1.3 F. HOFFMANN-LA ROCHE LTD.
                        11.1.3.1 Business overview
                        11.1.3.2 Products offered
                        11.1.3.3 Recent developments
                                     11.1.3.3.1 Product approvals
                                     11.1.3.3.2 Deals
                        11.1.3.4 MnM view
                                     11.1.3.4.1 Right to win
                                     11.1.3.4.2 Strategic choices
                                     11.1.3.4.3 Weaknesses and competitive threats
             11.1.4 PFIZER INC.
                        11.1.4.1 Business overview
                        11.1.4.2 Products offered
                        11.1.4.3 Recent developments
                                     11.1.4.3.1 Product approvals
                                     11.1.4.3.2 DEALS
                        11.1.4.4 MnM view
                                     11.1.4.4.1 Right to win
                                     11.1.4.4.2 Strategic choices
                                     11.1.4.4.3 Weaknesses and competitive threats
             11.1.5 BECTON, DICKINSON AND COMPANY
                        11.1.5.1 Business overview
                        11.1.5.2 Products offered
                        11.1.5.3 Recent developments
                                     11.1.5.3.1 Product launches
                                     11.1.5.3.2 Other developments
                        11.1.5.4 MnM view
                                     11.1.5.4.1 Right to win
                                     11.1.5.4.2 Strategic choices
                                     11.1.5.4.3 Weaknesses and competitive threats
             11.1.6 GLAXOSMITHKLINE PLC
                        11.1.6.1 Business overview
                        11.1.6.2 Products offered
                        11.1.6.3 Recent developments
                                     11.1.6.3.1 Product approvals
                                     11.1.6.3.2 Deals
                                     11.1.6.3.3 Other developments
             11.1.7 MERCK & CO., INC.
                        11.1.7.1 Business overview
                        11.1.7.2 Products offered
                        11.1.7.3 Recent developments
                                     11.1.7.3.1 Product approvals
                                     11.1.7.3.2 Deals
             11.1.8 SANOFI
                        11.1.8.1 Business overview
                        11.1.8.2 Products offered
                        11.1.8.3 Recent developments
                                     11.1.8.3.1 Product approvals
                                     11.1.8.3.2 Deals
             11.1.9 BAYER AG
                        11.1.9.1 Business overview
                        11.1.9.2 Products offered
                        11.1.9.3 Recent developments
                                     11.1.9.3.1 Product approvals
                                     11.1.9.3.2 Deals
                                     11.1.9.3.3 Expansions
             11.1.10 AMGEN, INC.
                        11.1.10.1 Business overview
                        11.1.10.2 Products offered
                        11.1.10.3 Recent developments
                                     11.1.10.3.1 Product approvals
                                     11.1.10.3.2 Deals
             11.1.11 ABBVIE INC.
                        11.1.11.1 Business overview
                        11.1.11.2 Products offered
                        11.1.11.3 Recent developments
                                     11.1.11.3.1 Product launches & approvals
                                     11.1.11.3.2 Deals
                                     11.1.11.3.3 Expansions
             11.1.12 GENMAB A/S
                        11.1.12.1 Business overview
                        11.1.12.2 Products offered
                        11.1.12.3 Recent developments
                                     11.1.12.3.1 Product approvals
                                     11.1.12.3.2 Deals
             11.1.13 GILEAD SCIENCES, INC.
                        11.1.13.1 Business overview
                        11.1.13.2 Products offered
                        11.1.13.3 Recent developments
                                     11.1.13.3.1 Product approvals
                                     11.1.13.3.2 Deals
                                     11.1.13.3.3 Other developments
             11.1.14 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
                        11.1.14.1 Business overview
                        11.1.14.2 Products offered
                        11.1.14.3 Recent developments
                                     11.1.14.3.1 Product approvals
                                     11.1.14.3.2 Deals
             11.1.15 ASTRAZENECA
                        11.1.15.1 Business overview
                        11.1.15.2 Products offered
                        11.1.15.3 Recent developments
                                     11.1.15.3.1 Product approvals
                                     11.1.15.3.2 Deals
             11.1.16 ELI LILLY AND COMPANY
                        11.1.16.1 Business overview
                        11.1.16.2 Products offered
                        11.1.16.3 Recent developments
                                     11.1.16.3.1 Product approvals
                                     11.1.16.3.2 Deals
                                     11.1.16.3.3 Expansions
             11.1.17 TEVA PHARMACEUTICAL INDUSTRIES LTD.
                        11.1.17.1 Business overview
                        11.1.17.2 Products offered
                        11.1.17.3 Recent developments
                                     11.1.17.3.1 Product approvals & launches
                                     11.1.17.3.2 Deals
     11.2 OTHER PLAYERS 
             11.2.1 NOVO NORDISK A/S
             11.2.2 GLENMARK PHARMACEUTICALS LTD.
             11.2.3 VIATRIS INC
             11.2.4 BRISTOL-MYERS SQUIBB COMPANY
             11.2.5 SANDOZ GROUP AG
             11.2.6 GERRESHEIMER AG
             11.2.7 BOSTON SCIENTIFIC CORPORATION
             11.2.8 CMP PHARMA
             11.2.9 RUSAN PHARMA
 
12 APPENDIX (Page No. - 709)
     12.1 DISCUSSION GUIDE 
     12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     12.3 CUSTOMIZATION OPTIONS 
     12.4 RELATED REPORTS 
     12.5 AUTHOR DETAILS 
 
 
LIST OF TABLES (907 TABLES)
 
TABLE 1 STANDARD EXCHANGE RATES FOR CONVERSION TO USD
TABLE 2 US FDA: INDICATIVE LIST OF APPROVED BIOLOGICS (2023)
TABLE 3 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,  AND OTHER ORGANIZATIONS
TABLE 4 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,  AND OTHER ORGANIZATIONS
TABLE 5 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,  AND OTHER ORGANIZATIONS
TABLE 6 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,  AND OTHER ORGANIZATIONS
TABLE 7 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES,  AND OTHER ORGANIZATIONS
TABLE 8 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,  AND OTHER ORGANIZATIONS
TABLE 9 IMPORT DATA FOR SYRINGES, WITH OR WITHOUT NEEDLES (HS CODE 901831), BY COUNTRY, 2019–2023 (USD THOUSAND)
TABLE 10 EXPORT DATA FOR SYRINGES, WITH OR WITHOUT NEEDLES (HS CODE 901831), BY COUNTRY, 2019–2023 (USD THOUSAND)
TABLE 11 IMPORT DATA FOR MEDICAMENTS IN MEASURED DOSES, INCLUDING TRANSDERMAL ADMINISTRATION (HS CODE 300490), BY COUNTRY,  2019–2023 (USD THOUSAND)
TABLE 12 EXPORT DATA FOR MEDICAMENTS IN MEASURED DOSES, INCLUDING TRANSDERMAL ADMINISTRATION (HS CODE 300490), BY COUNTRY,  2019–2023 (USD THOUSAND)
TABLE 13 INDICATIVE LIST OF PATENTS/PATENT APPLICATIONS IN PHARMACEUTICAL DRUG DELIVERY, 2023 –2024
TABLE 14 PHARMACEUTICAL DRUG DEVELOPMENT MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 15 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS, BY END USER
TABLE 16 KEY BUYING CRITERIA, BY END USER
TABLE 17 AVERAGE SELLING PRICE TREND OF PHARMACEUTICAL DRUG DELIVERY PRODUCTS, BY REGION
TABLE 18 LIST OF MAJOR CONFERENCES & EVENTS IN 2024–2025
TABLE 19 US: REIMBURSEMENT CODES FOR INJECTION
TABLE 20 US: REIMBURSEMENT CODES FOR INHALER TECHNIQUES
TABLE 21 US: REIMBURSEMENT CODES FOR CHEMOTHERAPY ADMINISTRATION
TABLE 22 CASE STUDY 1: ADVANCEMENTS IN TREATING DEPRESSION WITH NOVEL AND RAPIDLY ACTING DRUG DELIVERY TECHNOLOGY
TABLE 23 CASE STUDY 2: OVERCOMING SUPPLY CHAIN ROADBLOCKS FOR RELIABLE COMPLEX ORAL SOLID DOSE (OSD) DELIVERY AT PFIZER CENTREONE,  ASCOLI, ITALY
TABLE 24 PHARMACEUTICAL DRUG DELIVERY MARKET: END-USER EXPECTATIONS
TABLE 25 PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 26 INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 27 INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 28 CONVENTIONAL INJECTION DEVICES MARKET, BY COUNTRY,  2022–2029 (USD BILLION)
TABLE 29 CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,  2022–2029 (USD BILLION)
TABLE 30 GLASS SYRINGES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 31 PLASTIC SYRINGES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 32 CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,  2022–2029 (USD BILLION)
TABLE 33 FILLABLE SYRINGES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 34 PREFILLED SYRINGES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 35 CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,  2022–2029 (USD BILLION)
TABLE 36 REUSABLE SYRINGES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 37 DISPOSABLE SYRINGES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 38 SELF-INJECTION DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 39 SELF-INJECTION DEVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 40 NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 41 AUTOINJECTORS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 42 COMMERCIALLY AVAILABLE PEN INJECTORS
TABLE 43 PEN INJECTORS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 44 WEARABLE INJECTORS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 45 ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 46 ORAL DRUG DELIVERY MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 47 SOLID ORAL DRUGS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 48 SOLID ORAL DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 49 TABLETS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 50 CAPSULES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 51 ORAL POWDERS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 52 PILLS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 53 LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 54 LIQUID ORAL DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 55 ORAL SYRUPS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 56 ORAL SOLUTIONS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 57 ORAL EMULSIONS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 58 ORAL ELIXIRS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 59 SEMI-SOLID ORAL DRUGS, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 60 SEMI-SOLID ORAL DRUGS, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 61 ORAL GELS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 62 ORAL PASTES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 63 TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 64 TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 65 SEMI-SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 66 SEMI-SOLID TOPICAL FORMULATIONS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)
TABLE 67 TOPICAL CREAMS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 68 TOPICAL GELS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 69 TOPICAL OINTMENTS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 70 TOPICAL PASTES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 71 TOPICAL LOTIONS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 72 LIQUID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 73 LIQUID TOPICAL FORMULATIONS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)
TABLE 74 TOPICAL SUSPENSIONS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 75 TOPICAL EMULSIONS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 76 TOPICAL SOLUTIONS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 77 SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 78 SOLID TOPICAL FORMULATIONS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)
TABLE 79 TOPICAL POWDERS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 80 SUPPOSITORIES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 81 TRANSDERMAL PRODUCTS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 82 TRANSDERMAL PRODUCTS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 83 TRANSDERMAL PATCHES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 84 TRANSDERMAL GELS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 85 TRANSDERMAL SPRAYS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 86 OCULAR DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 87 OCULAR DRUG DELIVERY MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 88 LIQUID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 89 LIQUID OCULAR FORMULATIONS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)
TABLE 90 COMMERCIALLY AVAILABLE EYE DROPS
TABLE 91 EYE DROPS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 92 LIQUID OCULAR SPRAYS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 93 SEMI-SOLID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 94 SEMI-SOLID OCULAR FORMULATIONS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)
TABLE 95 OCULAR GELS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 96 EYE OINTMENTS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 97 OCULAR DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 98 OCULAR DEVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 99 OCULAR INSERTS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 100 DRUG-COATED CONTACT LENSES MARKET, BY COUNTRY,  2022–2029 (USD BILLION)
TABLE 101 PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 102 PULMONARY DRUG DELIVERY MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 103 METERED-DOSE INHALERS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 104 DRY POWDER INHALERS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 105 NEBULIZERS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 106 NEBULIZERS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 107 JET NEBULIZERS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 108 ULTRASONIC NEBULIZERS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 109 SOFT MIST NEBULIZERS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 110 NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 111 NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 112 NASAL SPRAYS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 113 NASAL DROPS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 114 NASAL GELS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 115 NASAL POWDERS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 116 TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 117 TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY,  2022–2029 (USD BILLION)
TABLE 118 ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 119 ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)
TABLE 120 BUCCAL DRUG DELIVERY MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 121 SUBLINGUAL DRUG DELIVERY MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 122 OTHER TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 123 OTHER TRANSMUCOSAL FORMULATIONS MARKET, BY COUNTRY,  2022–2029 (USD BILLION)
TABLE 124 RECTAL DRUG DELIVERY MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 125 VAGINAL DRUG DELIVERY MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 126 IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 127 IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 128 PASSIVE IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY,  2022–2029 (USD BILLION)
TABLE 129 ACTIVE IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY,  2022–2029 (USD BILLION)
TABLE 130 PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION,  2022–2029 (USD BILLION)
TABLE 131 PHARMACEUTICAL DRUG DELIVERY MARKET FOR INFECTIOUS DISEASES,  BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 132 LIST OF FDA-APPROVED DRUGS FOR ONCOLOGY (2024)
TABLE 133 PHARMACEUTICAL DRUG DELIVERY MARKET FOR CANCER, BY COUNTRY,  2022–2029 (USD BILLION)
TABLE 134 PHARMACEUTICAL DRUG DELIVERY MARKET FOR CVD, BY COUNTRY,  2022–2029 (USD BILLION)
TABLE 135 PHARMACEUTICAL DRUG DELIVERY MARKET FOR DIABETES, BY COUNTRY,  2022–2029 (USD BILLION)
TABLE 136 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISEASES (2023)
TABLE 137 PHARMACEUTICAL DRUG DELIVERY MARKET FOR RESPIRATORY DISEASES,  BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 138 PHARMACEUTICAL DRUG DELIVERY MARKET FOR CNS DISORDERS, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 139 PHARMACEUTICAL DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES,  BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 140 PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHER APPLICATIONS,  BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 141 PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,  2022–2029 (USD BILLION)
TABLE 142 PHARMACEUTICAL DRUG DELIVERY MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 143 PHARMACEUTICAL DRUG DELIVERY MARKET FOR ASCS/CLINICS, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 144 PHARMACEUTICAL DRUG DELIVERY MARKET FOR HOME CARE SETTINGS,  BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 145 PHARMACEUTICAL DRUG DELIVERY MARKET FOR DIAGNOSTIC CENTERS,  BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 146 PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHER FACILITIES OF USE,  BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 147 PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION,  2022–2029 (USD BILLION)
TABLE 148 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 149 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET,  BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 150 NORTH AMERICA: ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 151 NORTH AMERICA: SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 152 NORTH AMERICA: LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 153 NORTH AMERICA: SEMI-SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD MILLION)
TABLE 154 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 155 NORTH AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2022–2029 (USD BILLION)
TABLE 156 NORTH AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2022–2029 (USD BILLION)
TABLE 157 NORTH AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2022–2029 (USD BILLION)
TABLE 158 NORTH AMERICA: SELF-INJECTION DEVICES MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 159 NORTH AMERICA: OCULAR DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 160 NORTH AMERICA: LIQUID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 161 NORTH AMERICA: SEMI-SOLID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 162 NORTH AMERICA: OCULAR DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 163 NORTH AMERICA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 164 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 165 NORTH AMERICA: LIQUID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 166 NORTH AMERICA: SEMI-SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 167 NORTH AMERICA: SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 168 NORTH AMERICA: TRANSDERMAL PRODUCTS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 169 NORTH AMERICA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 170 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 171 NORTH AMERICA: ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 172 NORTH AMERICA: OTHER TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 173 NORTH AMERICA: PULMONARY DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 174 NORTH AMERICA: NEBULIZERS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 175 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 176 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2029 (USD BILLION)
TABLE 177 US: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 178 US: ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 179 US: SOLID ORAL DRUGS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 180 US: LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 181 US: SEMI-SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD MILLION)
TABLE 182 US: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 183 US: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,  2022–2029 (USD BILLION)
TABLE 184 US: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,  2022–2029 (USD BILLION)
TABLE 185 US: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,  2022–2029 (USD BILLION)
TABLE 186 US: SELF-INJECTION DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 187 US: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 188 US: LIQUID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 189 US: SEMI-SOLID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 190 US: OCULAR DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 191 US: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 192 US: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 193 US: LIQUID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 194 US: SEMI-SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 195 US: SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 196 US: TRANSDERMAL PRODUCTS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 197 US: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 198 US: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 199 US: ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 200 US: OTHER TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 201 US: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 202 US: NEBULIZERS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 203 US: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION,  2022–2029 (USD BILLION)
TABLE 204 US: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,  2022–2029 (USD BILLION)
TABLE 205 CANADA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 206 CANADA: ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 207 CANADA: SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 208 CANADA: LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 209 CANADA: SEMI-SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 210 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 211 CANADA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,  2022–2029 (USD BILLION)
TABLE 212 CANADA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,  2022–2029 (USD BILLION)
TABLE 213 CANADA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,  2022–2029 (USD BILLION)
TABLE 214 CANADA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 215 CANADA: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 216 CANADA: LIQUID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 217 CANADA: SEMI-SOLID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 218 CANADA: OCULAR DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 219 CANADA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 220 CANADA: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 221 CANADA: LIQUID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 222 CANADA: SEMI-SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 223 CANADA: SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 224 CANADA: TRANSDERMAL PRODUCTS MARKET, BY TYPE 2022–2029 (USD BILLION)
TABLE 225 CANADA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD MILLION)
TABLE 226 CANADA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 227 CANADA: ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 228 CANADA: OTHER TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD MILLION)
TABLE 229 CANADA: PULMONARY DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 230 CANADA: NEBULIZERS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 231 CANADA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION,  2022–2029 (USD BILLION)
TABLE 232 CANADA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,  2022–2029 (USD BILLION)
TABLE 233 EUROPE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY,  2022–2029 (USD BILLION)
TABLE 234 EUROPE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 235 EUROPE: ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 236 EUROPE: SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 237 EUROPE: LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 238 EUROPE: SEMI-SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 239 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 240 EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,  2022–2029 (USD BILLION)
TABLE 241 EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,  2022–2029 (USD BILLION)
TABLE 242 EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,  2022–2029 (USD BILLION)
TABLE 243 EUROPE: SELF-INJECTION DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 244 EUROPE: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 245 EUROPE: LIQUID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 246 EUROPE: SEMI-SOLID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 247 EUROPE: OCULAR DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 248 EUROPE: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 249 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 250 EUROPE: LIQUID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 251 EUROPE: SEMI-SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 252 EUROPE: SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 253 EUROPE: TRANSDERMAL PRODUCTS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 254 EUROPE: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 255 EUROPE: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 256 EUROPE: ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 257 EUROPE: OTHER TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 258 EUROPE: PULMONARY DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 259 EUROPE: NEBULIZERS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 260 EUROPE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION,  2022–2029 (USD BILLION)
TABLE 261 EUROPE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2029 (USD BILLION)
TABLE 262 GERMANY: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 263 GERMANY: ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 264 GERMANY: SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 265 GERMANY: LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 266 GERMANY: SEMI-SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 267 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 268 GERMANY: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,  2022–2029 (USD BILLION)
TABLE 269 GERMANY: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,  2022–2029 (USD BILLION)
TABLE 270 GERMANY: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,  2022–2029 (USD BILLION)
TABLE 271 GERMANY: SELF-INJECTION DEVICES MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 272 GERMANY: OCULAR DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 273 GERMANY: LIQUID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 274 GERMANY: SEMI-SOLID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 275 GERMANY: OCULAR DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 276 GERMANY: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 277 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 278 GERMANY: LIQUID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 279 GERMANY: SEMI-SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 280 GERMANY: SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 281 GERMANY: TRANSDERMAL PRODUCTS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 282 GERMANY: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD MILLION)
TABLE 283 GERMANY: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 284 GERMANY: ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 285 GERMANY: OTHER TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD MILLION)
TABLE 286 GERMANY: PULMONARY DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 287 GERMANY: NEBULIZERS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 288 GERMANY: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION,  2022–2029 (USD BILLION)
TABLE 289 GERMANY: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2029 (USD BILLION)
TABLE 290 FRANCE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 291 FRANCE: ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 292 FRANCE: SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 293 FRANCE: LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 294 FRANCE: SEMI-SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 295 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 296 FRANCE: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,  2022–2029 (USD BILLION)
TABLE 297 FRANCE: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,  2022–2029 (USD BILLION)
TABLE 298 FRANCE: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,  2022–2029 (USD BILLION)
TABLE 299 FRANCE: SELF-INJECTION DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 300 FRANCE: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 301 FRANCE: LIQUID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 302 FRANCE: SEMI-SOLID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 303 FRANCE: OCULAR DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 304 FRANCE: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 305 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 306 FRANCE: LIQUID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 307 FRANCE: SEMI-SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 308 FRANCE: SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 309 FRANCE: TRANSDERMAL PRODUCTS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 310 FRANCE: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD MILLION)
TABLE 311 FRANCE: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 312 FRANCE: ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 313 FRANCE: OTHER TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD MILLION)
TABLE 314 FRANCE: PULMONARY DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 315 FRANCE: NEBULIZERS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 316 FRANCE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION,  2022–2029 (USD BILLION)
TABLE 317 FRANCE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,  2022–2029 (USD BILLION)
TABLE 318 ITALY: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 319 ITALY: ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 320 ITALY: SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 321 ITALY: LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 322 ITALY: SEMI-SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 323 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 324 ITALY: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,  2022–2029 (USD BILLION)
TABLE 325 ITALY: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,  2022–2029 (USD BILLION)
TABLE 326 ITALY: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,  2022–2029 (USD BILLION)
TABLE 327 ITALY: SELF-INJECTION DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 328 ITALY: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 329 ITALY: LIQUID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 330 ITALY: SEMI-SOLID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 331 ITALY: OCULAR DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 332 ITALY: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 333 ITALY: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 334 ITALY: LIQUID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 335 ITALY: SEMI-SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 336 ITALY: SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 337 ITALY: TRANSDERMAL PRODUCTS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 338 ITALY: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD MILLION)
TABLE 339 ITALY: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 340 ITALY: ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 341 ITALY: OTHER TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD MILLION)
TABLE 342 ITALY: PULMONARY DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 343 ITALY: NEBULIZERS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 344 ITALY: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION,  2022–2029 (USD BILLION)
TABLE 345 ITALY: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,  2022–2029 (USD BILLION)
TABLE 346 UK: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 347 UK: ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 348 UK: SOLID ORAL DRUGS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 349 UK: LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 350 UK: SEMI-SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 351 UK: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 352 UK: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,  2022–2029 (USD BILLION)
TABLE 353 UK: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,  2022–2029 (USD BILLION)
TABLE 354 UK: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,  2022–2029 (USD BILLION)
TABLE 355 UK: SELF-INJECTION DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 356 UK: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 357 UK: LIQUID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 358 UK: SEMI-SOLID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 359 UK: OCULAR DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 360 UK: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 361 UK: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 362 UK: LIQUID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 363 UK: SEMI-SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 364 UK: SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 365 UK: TRANSDERMAL PRODUCTS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 366 UK: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 367 UK: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 368 UK: ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 369 UK: OTHER TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD MILLION)
TABLE 370 UK: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 371 UK: NEBULIZERS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 372 UK: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION,  2022–2029 (USD BILLION)
TABLE 373 UK: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,  2022–2029 (USD BILLION)
TABLE 374 SPAIN: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 375 SPAIN: ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 376 SPAIN: SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 377 SPAIN: LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 378 SPAIN: SEMI-SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 379 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 380 SPAIN: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,  2022–2029 (USD BILLION)
TABLE 381 SPAIN: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,  2022–2029 (USD BILLION)
TABLE 382 SPAIN: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,  2022–2029 (USD BILLION)
TABLE 383 SPAIN: SELF-INJECTION DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 384 SPAIN: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 385 SPAIN: LIQUID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 386 SPAIN: SEMI-SOLID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 387 SPAIN: OCULAR DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 388 SPAIN: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 389 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 390 SPAIN: LIQUID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 391 SPAIN: SEMI-SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 392 SPAIN: SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 393 SPAIN: TRANSDERMAL PRODUCTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 394 SPAIN: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD MLLION)
TABLE 395 SPAIN: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 396 SPAIN: ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 397 SPAIN: OTHER TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD MILLION)
TABLE 398 SPAIN: PULMONARY DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 399 SPAIN: NEBULIZERS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 400 SPAIN: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION,  2022–2029 (USD MILLION)
TABLE 401 SPAIN: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,  2022–2029 (USD BILLION)
TABLE 402 REST OF EUROPE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 403 REST OF EUROPE: ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 404 REST OF EUROPE: SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 405 REST OF EUROPE: LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 406 REST OF EUROPE: SEMI-SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 407 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 408 REST OF EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2022–2029 (USD BILLION)
TABLE 409 REST OF EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2022–2029 (USD BILLION)
TABLE 410 REST OF EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2022–2029 (USD BILLION)
TABLE 411 REST OF EUROPE: SELF-INJECTION DEVICES MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 412 REST OF EUROPE: OCULAR DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 413 REST OF EUROPE: LIQUID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 414 REST OF EUROPE: SEMI-SOLID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 415 REST OF EUROPE: OCULAR DEVICES MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 416 REST OF EUROPE: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 417 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 418 REST OF EUROPE: LIQUID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 419 REST OF EUROPE: SEMI-SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 420 REST OF EUROPE: SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 421 REST OF EUROPE: TRANSDERMAL PRODUCTS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 422 REST OF EUROPE: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD MILLION)
TABLE 423 REST OF EUROPE: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 424 REST OF EUROPE: ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 425 REST OF EUROPE: OTHER TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 426 REST OF EUROPE: PULMONARY DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 427 REST OF EUROPE: NEBULIZERS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 428 REST OF EUROPE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 429 REST OF EUROPE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2029 (USD BILLION)
TABLE 430 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 431 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 432 ASIA PACIFIC: ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 433 ASIA PACIFIC: SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 434 ASIA PACIFIC: LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 435 ASIA PACIFIC: SEMI-SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 436 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 437 ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,  2022–2029 (USD BILLION)
TABLE 438 ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,  2022–2029 (USD BILLION)
TABLE 439 ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,  2022–2029 (USD BILLION)
TABLE 440 ASIA PACIFIC: SELF-INJECTION DEVICES MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 441 ASIA PACIFIC: OCULAR DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 442 ASIA PACIFIC: LIQUID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 443 ASIA PACIFIC: SEMI-SOLID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 444 ASIA PACIFIC: OCULAR DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 445 ASIA PACIFIC: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 446 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 447 ASIA PACIFIC: LIQUID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 448 ASIA PACIFIC: SEMI-SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 449 ASIA PACIFIC: SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 450 ASIA PACIFIC: TRANSDERMAL PRODUCTS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 451 ASIA PACIFIC: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 452 ASIA PACIFIC: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 453 ASIA PACIFIC: ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 454 ASIA PACIFIC: OTHER TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 455 ASIA PACIFIC: PULMONARY DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 456 ASIA PACIFIC: NEBULIZERS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 457 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 458 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2029 (USD BILLION)
TABLE 459 CHINA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 460 CHINA: ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 461 CHINA: SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 462 CHINA: LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 463 CHINA: SEMI-SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 464 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 465 CHINA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,  2022–2029 (USD BILLION)
TABLE 466 CHINA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,  2022–2029 (USD BILLION)
TABLE 467 CHINA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,  2022–2029 (USD BILLION)
TABLE 468 CHINA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 469 CHINA: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 470 CHINA: LIQUID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 471 CHINA: SEMI-SOLID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 472 CHINA: OCULAR DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 473 CHINA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 474 CHINA: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 475 CHINA: LIQUID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 476 CHINA: SEMI-SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 477 CHINA: SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 478 CHINA: TRANSDERMAL PRODUCTS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 479 CHINA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 480 CHINA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 481 CHINA: ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 482 CHINA: OTHER TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 483 CHINA: PULMONARY DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 484 CHINA: NEBULIZERS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 485 CHINA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION,  2022–2029 (USD BILLION)
TABLE 486 CHINA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,  2022–2029 (USD BILLION)
TABLE 487 JAPAN: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 488 JAPAN: ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 489 JAPAN: SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 490 JAPAN: LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 491 JAPAN: SEMI-SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 492 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 493 JAPAN: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,  2022–2029 (USD BILLION)
TABLE 494 JAPAN: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,  2022–2029 (USD BILLION)
TABLE 495 JAPAN: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,  2022–2029 (USD BILLION)
TABLE 496 JAPAN: SELF-INJECTION DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 497 JAPAN: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 498 JAPAN: LIQUID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 499 JAPAN: SEMI-SOLID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 500 JAPAN: OCULAR DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 501 JAPAN: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 502 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 503 JAPAN: LIQUID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 504 JAPAN: SEMI-SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 505 JAPAN: SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 506 JAPAN: TRANSDERMAL PRODUCTS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 507 JAPAN: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 508 JAPAN: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 509 JAPAN: ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 510 JAPAN: OTHER TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 511 JAPAN: PULMONARY DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 512 JAPAN: NEBULIZERS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 513 JAPAN: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION,  2022–2029 (USD BILLION)
TABLE 514 JAPAN: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,  2022–2029 (USD BILLION)
TABLE 515 INDIA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 516 INDIA: ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 517 INDIA: SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 518 INDIA: LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 519 INDIA: SEMI-SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 520 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 521 INDIA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,  2022–2029 (USD BILLION)
TABLE 522 INDIA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,  2022–2029 (USD BILLION)
TABLE 523 INDIA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,  2022–2029 (USD BILLION)
TABLE 524 INDIA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 525 INDIA: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 526 INDIA: LIQUID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 527 INDIA: SEMI-SOLID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 528 INDIA: OCULAR DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 529 INDIA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2023 (USD BILLION)
TABLE 530 INDIA: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 531 INDIA: LIQUID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 532 INDIA: SEMI-SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 533 INDIA: SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 534 INDIA: TRANSDERMAL PRODUCTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 535 INDIA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD MILLION)
TABLE 536 INDIA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 537 INDIA: ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 538 INDIA: OTHER TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 539 INDIA: PULMONARY DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 540 INDIA: NEBULIZERS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 541 INDIA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION,  2022–2029 (USD BILLION)
TABLE 542 INDIA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,  2022–2029 (USD BILLION)
TABLE 543 AUSTRALIA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 544 AUSTRALIA: ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 545 AUSTRALIA: SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 546 AUSTRALIA: LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 547 AUSTRALIA: SEMI-SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 548 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 549 AUSTRALIA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,  2022–2029 (USD BILLION)
TABLE 550 AUSTRALIA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,  2022–2029 (USD BILLION)
TABLE 551 AUSTRALIA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,  2022–2029 (USD BILLION)
TABLE 552 AUSTRALIA: SELF-INJECTION DEVICES MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 553 AUSTRALIA: OCULAR DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 554 AUSTRALIA: LIQUID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 555 AUSTRALIA: SEMI-SOLID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 556 AUSTRALIA: OCULAR DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 557 AUSTRALIA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2023 (USD BILLION)
TABLE 558 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 559 AUSTRALIA: LIQUID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 560 AUSTRALIA: SEMI-SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 561 AUSTRALIA: SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 562 AUSTRALIA: TRANSDERMAL PRODUCTS MARKET, BY TYPE,  2022–2029 (USD MILLION)
TABLE 563 AUSTRALIA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD MILLION)
TABLE 564 AUSTRALIA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 565 AUSTRALIA: ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 566 AUSTRALIA: OTHER TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 567 AUSTRALIA: PULMONARY DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 568 AUSTRALIA: NEBULIZERS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 569 AUSTRALIA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION,  2022–2029 (USD BILLION)
TABLE 570 AUSTRALIA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2029 (USD BILLION)
TABLE 571 SOUTH KOREA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 572 SOUTH KOREA: ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 573 SOUTH KOREA: SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 574 SOUTH KOREA: LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 575 SOUTH KOREA: SEMI-SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 576 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 577 SOUTH KOREA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2022–2029 (USD BILLION)
TABLE 578 SOUTH KOREA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2022–2029 (USD BILLION)
TABLE 579 SOUTH KOREA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2022–2029 (USD BILLION)
TABLE 580 SOUTH KOREA: SELF-INJECTION DEVICES MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 581 SOUTH KOREA: OCULAR DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 582 SOUTH KOREA: LIQUID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 583 SOUTH KOREA: SEMI-SOLID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 584 SOUTH KOREA: OCULAR DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 585 SOUTH KOREA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2023 (USD BILLION)
TABLE 586 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 587 SOUTH KOREA: LIQUID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 588 SOUTH KOREA: SEMI-SOLID TOPICAL FORMULATIONS MARKET,  BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 589 SOUTH KOREA: SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 590 SOUTH KOREA: TRANSDERMAL PRODUCTS MARKET, BY TYPE,  2022–2029 (USD MILLION)
TABLE 591 SOUTH KOREA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD MILLION)
TABLE 592 SOUTH KOREA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 593 SOUTH KOREA: ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 594 SOUTH KOREA: OTHER TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 595 SOUTH KOREA: PULMONARY DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 596 SOUTH KOREA: NEBULIZERS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 597 SOUTH KOREA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 598 SOUTH KOREA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2029 (USD BILLION)
TABLE 599 REST OF ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 600 REST OF ASIA PACIFIC: ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 601 REST OF ASIA PACIFIC: SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 602 REST OF ASIA PACIFIC: LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 603 REST OF ASIA PACIFIC: SEMI-SOLID ORAL DRUGS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 604 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 605 REST OF ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET,  BY MATERIAL, 2022–2029 (USD BILLION)
TABLE 606 REST OF ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET,  BY PRODUCT, 2022–2029 (USD BILLION)
TABLE 607 REST OF ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET,  BY USABILITY, 2022–2029 (USD BILLION)
TABLE 608 REST OF ASIA PACIFIC: SELF-INJECTION DEVICES MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 609 REST OF ASIA PACIFIC: OCULAR DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 610 REST OF ASIA PACIFIC: LIQUID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 611 REST OF ASIA PACIFIC: SEMI-SOLID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 612 REST OF ASIA PACIFIC: OCULAR DEVICES MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 613 REST OF ASIA PACIFIC: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 614 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 615 REST OF ASIA PACIFIC: LIQUID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 616 REST OF ASIA PACIFIC: SEMI-SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 617 REST OF ASIA PACIFIC: SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 618 REST OF ASIA PACIFIC: TRANSDERMAL PRODUCTS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 619 REST OF ASIA PACIFIC: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD MILLION)
TABLE 620 REST OF ASIA PACIFIC: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 621 REST OF ASIA PACIFIC: ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 622 REST OF ASIA PACIFIC: OTHER TRANSMUCOSAL FORMULATIONS MARKET,  BY TYPE, 2022–2029 (USD MILLION)
TABLE 623 REST OF ASIA PACIFIC: PULMONARY DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 624 REST OF ASIA PACIFIC: NEBULIZERS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 625 REST OF ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET,  BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 626 REST OF ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2029 (USD BILLION)
TABLE 627 LATIN AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 628 LATIN AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 629 LATIN AMERICA: ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 630 LATIN AMERICA: SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 631 LATIN AMERICA: LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 632 LATIN AMERICA: SEMI-SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 633 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 634 LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2022–2029 (USD BILLION)
TABLE 635 LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2022–2029 (USD BILLION)
TABLE 636 LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2022–2029 (USD BILLION)
TABLE 637 LATIN AMERICA: SELF-INJECTION DEVICES MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 638 LATIN AMERICA: OCULAR DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 639 LATIN AMERICA: LIQUID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 640 LATIN AMERICA: SEMI-SOLID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 641 LATIN AMERICA: OCULAR DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 642 LATIN AMERICA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 643 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 644 LATIN AMERICA: LIQUID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 645 LATIN AMERICA: SEMI-SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 646 LATIN AMERICA: SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 647 LATIN AMERICA: TRANSDERMAL PRODUCTS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 648 LATIN AMERICA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 649 LATIN AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 650 LATIN AMERICA: ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 651 LATIN AMERICA: OTHER TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 652 LATIN AMERICA: PULMONARY DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 653 LATIN AMERICA: NEBULIZERS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 654 LATIN AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 655 LATIN AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2029 (USD BILLION)
TABLE 656 BRAZIL: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 657 BRAZIL: ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 658 BRAZIL: SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 659 BRAZIL: LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 660 BRAZIL: SEMI-SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 661 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 662 BRAZIL: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,  2022–2029 (USD BILLION)
TABLE 663 BRAZIL: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,  2022–2029 (USD BILLION)
TABLE 664 BRAZIL: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,  2022–2029 (USD BILLION)
TABLE 665 BRAZIL: SELF-INJECTION DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 666 BRAZIL: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 667 BRAZIL: LIQUID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 668 BRAZIL: SEMI-SOLID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 669 BRAZIL: OCULAR DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 670 BRAZIL: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 671 BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 672 BRAZIL: LIQUID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 673 BRAZIL: SEMI-SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 674 BRAZIL: SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 675 BRAZIL: TRANSDERMAL PRODUCTS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 676 BRAZIL: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 677 BRAZIL: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 678 BRAZIL: ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 679 BRAZIL: OTHER TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD MILLION)
TABLE 680 BRAZIL: PULMONARY DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 681 BRAZIL: NEBULIZERS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 682 BRAZIL: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION,  2022–2029 (USD BILLION)
TABLE 683 BRAZIL: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,  2022–2029 (USD BILLION)
TABLE 684 MEXICO: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 685 MEXICO: ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 686 MEXICO: SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 687 MEXICO: LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 688 MEXICO: SEMI-SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 689 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 690 MEXICO: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,  2022–2029 (USD BILLION)
TABLE 691 MEXICO: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,  2022–2029 (USD BILLION)
TABLE 692 MEXICO: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,  2022–2029 (USD BILLION)
TABLE 693 MEXICO: SELF-INJECTION DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 694 MEXICO: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 695 MEXICO: LIQUID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 696 MEXICO: SEMI-SOLID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 697 MEXICO: OCULAR DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 698 MEXICO: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 699 MEXICO: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 700 MEXICO: LIQUID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 701 MEXICO: SEMI-SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 702 MEXICO: SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 703 MEXICO: TRANSDERMAL PRODUCTS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 704 MEXICO: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 705 MEXICO: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 706 MEXICO: ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 707 MEXICO: OTHER TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  2022–2029 (USD MILLION)
TABLE 708 MEXICO: PULMONARY DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 709 MEXICO: NEBULIZERS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 710 MEXICO: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION,  2022–2029 (USD BILLION)
TABLE 711 MEXICO: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,  2022–2029 (USD BILLION)
TABLE 712 REST OF LATIN AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 713 REST OF LATIN AMERICA: ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 714 REST OF LATIN AMERICA: SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 715 REST OF LATIN AMERICA: LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 716 REST OF LATIN AMERICA: SEMI-SOLID ORAL DRUGS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 717 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 718 REST OF LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET,  BY MATERIAL, 2022–2029 (USD BILLION)
TABLE 719 REST OF LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET,  BY PRODUCT, 2022–2029 (USD BILLION)
TABLE 720 REST OF LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET,  BY USABILITY, 2022–2029 (USD BILLION)
TABLE 721 REST OF LATIN AMERICA: SELF-INJECTION DEVICES MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 722 REST OF LATIN AMERICA: OCULAR DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 723 REST OF LATIN AMERICA: LIQUID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 724 REST OF LATIN AMERICA: SEMI-SOLID OCULAR FORMULATIONS MARKET,  BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 725 REST OF LATIN AMERICA: OCULAR DEVICES MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 726 REST OF LATIN AMERICA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 727 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 728 REST OF LATIN AMERICA: LIQUID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 729 REST OF LATIN AMERICA: SEMI-SOLID TOPICAL FORMULATIONS MARKET,  BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 730 REST OF LATIN AMERICA: SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 731 REST OF LATIN AMERICA: TRANSDERMAL PRODUCTS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 732 REST OF LATIN AMERICA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 733 REST OF LATIN AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 734 REST OF LATIN AMERICA: ORAL TRANSMUCOSAL FORMULATIONS MARKET,  BY TYPE, 2022–2029 (USD BILLION)
TABLE 735 REST OF LATIN AMERICA: OTHER TRANSMUCOSAL FORMULATIONS MARKET,  BY TYPE, 2022–2029 (USD BILLION)
TABLE 736 REST OF LATIN AMERICA: PULMONARY DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 737 REST OF LATIN AMERICA: NEBULIZERS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 738 REST OF LATIN AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET,  BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 739 REST OF LATIN AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET,  BY FACILITY OF USE, 2022–2029 (USD BILLION)
TABLE 740 MIDDLE EAST & AFRICA: BY REGION, 2022–2029 (USD BILLION)
TABLE 741 MIDDLE EAST & AFRICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 742 MIDDLE EAST & AFRICA: ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 743 MIDDLE EAST & AFRICA: SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 744 MIDDLE EAST & AFRICA: LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 745 MIDDLE EAST & AFRICA: SEMI-SOLID ORAL DRUGS MARKET, BY DOSAGE FORM, 2022–2029 (USD MILLION)
TABLE 746 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 747 MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET,  BY MATERIAL, 2022–2029 (USD BILLION)
TABLE 748 MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET,  BY PRODUCT, 2022–2029 (USD BILLION)
TABLE 749 MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET,  BY USABILITY, 2022–2029 (USD BILLION)
TABLE 750 MIDDLE EAST & AFRICA: SELF-INJECTION DEVICES MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 751 MIDDLE EAST & AFRICA: OCULAR DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 752 MIDDLE EAST & AFRICA: LIQUID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 753 MIDDLE EAST & AFRICA: SEMI-SOLID OCULAR FORMULATIONS MARKET,  BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 754 MIDDLE EAST & AFRICA: OCULAR DEVICES MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 755 MIDDLE EAST & AFRICA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2022–2029 (USD MILLION)
TABLE 756 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 757 MIDDLE EAST & AFRICA: LIQUID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 758 MIDDLE EAST & AFRICA: SEMI-SOLID TOPICAL FORMULATIONS MARKET,  BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 759 MIDDLE EAST & AFRICA: SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 760 MIDDLE EAST & AFRICA: TRANSDERMAL PRODUCTS MARKET, BY TYPE,  2022–2029 (USD MILLION)
TABLE 761 MIDDLE EAST & AFRICA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD MILLION)
TABLE 762 MIDDLE EAST & AFRICA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 763 MIDDLE EAST & AFRICA: ORAL TRANSMUCOSAL FORMULATIONS MARKET,  BY TYPE, 2022–2029 (USD BILLION)
TABLE 764 MIDDLE EAST & AFRICA: OTHER TRANSMUCOSAL FORMULATIONS MARKET,  BY TYPE, 2022–2029 (USD MILLION)
TABLE 765 MIDDLE EAST & AFRICA: PULMONARY DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 766 MIDDLE EAST & AFRICA: NEBULIZERS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 767 MIDDLE EAST & AFRICA: PHARMACEUTICAL DRUG DELIVERY MARKET,  BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 768 MIDDLE EAST & AFRICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2029 (USD BILLION)
TABLE 769 GCC COUNTRIES: PHARMACEUTICAL DRUG DELIVERY MARKET,  BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 770 GCC COUNTRIES: ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 771 GCC COUNTRIES: SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 772 GCC COUNTRIES: LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD BILLION)
TABLE 773 GCC COUNTRIES: SEMI-SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  2022–2029 (USD MILLION)
TABLE 774 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 775 GCC COUNTRIES: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2022–2029 (USD BILLION)
TABLE 776 GCC COUNTRIES: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2022–2029 (USD BILLION)
TABLE 777 GCC COUNTRIES: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2022–2029 (USD BILLION)
TABLE 778 GCC COUNTRIES: SELF-INJECTION DEVICES MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 779 GCC COUNTRIES: OCULAR DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 780 GCC COUNTRIES: LIQUID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 781 GCC COUNTRIES: SEMI-SOLID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 782 GCC COUNTRIES: OCULAR DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 783 GCC COUNTRIES: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM,  2022–2029 (USD MILLION)
TABLE 784 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 785 GCC COUNTRIES: LIQUID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 786 GCC COUNTRIES: SEMI-SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 787 GCC COUNTRIES: SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 788 GCC COUNTRIES: TRANSDERMAL PRODUCTS MARKET, BY TYPE,  2022–2029 (USD MILLION)
TABLE 789 GCC COUNTRIES: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD MILLION)
TABLE 790 GCC COUNTRIES: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD MILLION)
TABLE 791 GCC COUNTRIES: ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 792 GCC COUNTRIES: OTHER TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 793 GCC COUNTRIES: PULMONARY DRUG DELIVERY MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 794 GCC COUNTRIES: NEBULIZERS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 795 GCC COUNTRIES: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 796 GCC COUNTRIES: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2029 (USD BILLION)
TABLE 797 REST OF MIDDLE EAST & AFRICA: PHARMACEUTICAL DRUG DELIVERY MARKET,  BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 798 REST OF MIDDLE EAST & AFRICA: ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 799 REST OF MIDDLE EAST & AFRICA: SOLID ORAL DRUGS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 800 REST OF MIDDLE EAST & AFRICA: LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 801 REST OF MIDDLE EAST & AFRICA: SEMI-SOLID ORAL DRUGS MARKET, BY DOSAGE FORM, 2022–2029 (USD MILLION)
TABLE 802 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 803 REST OF MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2022–2029 (USD BILLION)
TABLE 804 REST OF MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2022–2029 (USD BILLION)
TABLE 805 REST OF MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2022–2029 (USD BILLION)
TABLE 806 REST OF MIDDLE EAST & AFRICA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 807 REST OF MIDDLE EAST & AFRICA: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 808 REST OF MIDDLE EAST & AFRICA: LIQUID OCULAR FORMULATIONS MARKET,  BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 809 REST OF MIDDLE EAST & AFRICA: SEMI-SOLID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 810 REST OF MIDDLE EAST & AFRICA: OCULAR DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 811 REST OF MIDDLE EAST & AFRICA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2022–2029 (USD MILLION)
TABLE 812 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 813 REST OF MIDDLE EAST & AFRICA: LIQUID TOPICAL FORMULATIONS MARKET,  BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 814 REST OF MIDDLE EAST & AFRICA: SEMI-SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 815 REST OF MIDDLE EAST & AFRICA: SOLID TOPICAL FORMULATIONS MARKET,  BY DOSAGE FORM, 2022–2029 (USD BILLION)
TABLE 816 REST OF MIDDLE EAST & AFRICA: TRANSDERMAL PRODUCTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 817 REST OF MIDDLE EAST & AFRICA: IMPLANTABLE DRUG DELIVERY MARKET,  BY TYPE, 2022–2029 (USD MILLION)
TABLE 818 REST OF MIDDLE EAST & AFRICA: TRANSMUCOSAL DRUG DELIVERY MARKET,  BY TYPE, 2022–2029 (USD MILLION)
TABLE 819 REST OF MIDDLE EAST & AFRICA: ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 820 REST OF MIDDLE EAST & AFRICA: OTHER TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 821 REST OF MIDDLE EAST & AFRICA: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 822 REST OF MIDDLE EAST & AFRICA: NEBULIZERS MARKET, BY TYPE,  2022–2029 (USD BILLION)
TABLE 823 REST OF MIDDLE EAST & AFRICA: PHARMACEUTICAL DRUG DELIVERY MARKET,  BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 824 REST OF MIDDLE EAST & AFRICA: PHARMACEUTICAL DRUG DELIVERY MARKET,  BY FACILITY OF USE, 2022–2029 (USD BILLION)
TABLE 825 PHARMACEUTICAL DRUG DELIVERY MARKET: DEGREE OF COMPETITION
TABLE 826 PHARMACEUTICAL DRUG DELIVERY MARKET: ROUTE OF ADMINISTRATION FOOTPRINT
TABLE 827 PHARMACEUTICAL DRUG DELIVERY MARKET: REGION FOOTPRINT
TABLE 828 PHARMACEUTICAL DRUG DELIVERY MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 829 PHARMACEUTICAL DRUG DELIVERY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
TABLE 830 PHARMACEUTICAL DRUG DELIVERY MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2024
TABLE 831 PHARMACEUTICAL DRUG DELIVERY MARKET: DEALS, JANUARY 2021–MAY 2024
TABLE 832 PHARMACEUTICAL DRUG DELIVERY MARKET: EXPANSIONS,  JANUARY 2021–MAY 2024
TABLE 833 PHARMACEUTICAL DRUG DELIVERY MARKET: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
TABLE 834 JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW
TABLE 835 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED
TABLE 836 JOHNSON & JOHNSON SERVICES, INC.: PRODUCT APPROVALS,  JANUARY 2021–MAY 2024
TABLE 837 JOHNSON & JOHNSON SERVICES, INC.: DEALS, JANUARY 2021–MAY 2024
TABLE 838 JOHNSON & JOHNSON SERVICES, INC.: OTHER DEVELOPMENTS,  JANUARY 2021–MAY 2024
TABLE 839 NOVARTIS AG: COMPANY OVERVIEW
TABLE 840 NOVARTIS AG.: PRODUCTS OFFERED
TABLE 841 NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
TABLE 842 NOVARTIS AG: DEALS, JANUARY 2021–MAY 2024
TABLE 843 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
TABLE 844 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
TABLE 845 F. HOFFMANN-LA ROCHE LTD.: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
TABLE 846 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021–MAY 2024
TABLE 847 PFIZER INC.: COMPANY OVERVIEW
TABLE 848 PFIZER INC.: PRODUCTS OFFERED
TABLE 849 PFIZER INC.: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
TABLE 850 PFIZER INC.: DEALS, JANUARY 2021–MAY 2024
TABLE 851 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
TABLE 852 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED
TABLE 853 BECTON DICKINSON AND COMPANY: PRODUCT LAUNCHES,  JANUARY 2021–MAY 2024
TABLE 854 BECTON DICKINSON AND COMPANY: OTHER DEVELOPMENTS,  JANUARY 2021–MAY 2024
TABLE 855 GLAXOSMITHKLINE PLC: COMPANY OVERVIEW
TABLE 856 GLAXOSMITHKLINE PLC: PRODUCTS OFFERED
TABLE 857 GLAXOSMITHKLINE PLC: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
TABLE 858 GLAXOSMITHKLINE PLC: DEALS, JANUARY 2021–MAY 2024
TABLE 859 GLAXOSMITHKLINE PLC: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
TABLE 860 MERCK & CO., INC.: COMPANY OVERVIEW
TABLE 861 MERCK & CO., INC.: PRODUCTS OFFERED
TABLE 862 MERCK & CO., INC: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
TABLE 863 MERCK & CO., INC: DEALS, JANUARY 2021–MAY 2024
TABLE 864 SANOFI: COMPANY OVERVIEW
TABLE 865 SANOFI: PRODUCTS OFFERED
TABLE 866 SANOFI: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
TABLE 867 SANOFI: DEALS, JANUARY 2021–MAY 2024
TABLE 868 BAYER AG: COMPANY OVERVIEW
TABLE 869 BAYER AG: COMPANY OVERVIEW
TABLE 870 BAYER AG: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
TABLE 871 BAYER AG: DEALS, JANUARY 2021–MAY 2024
TABLE 872 BAYER AG: EXPANSIONS, JANUARY 2021–MAY 2024
TABLE 873 AMGEN, INC.: COMPANY OVERVIEW
TABLE 874 AMGEN, INC.: PRODUCTS OFFERED
TABLE 875 AMGEN, INC.: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
TABLE 876 AMGEN, INC.: DEALS, JANUARY 2021–MAY 2024
TABLE 877 ABBVIE INC.: COMPANY OVERVIEW
TABLE 878 ABBVIE, INC.: PRODUCTS OFFERED
TABLE 879 ABBVIE INC.: PRODUCT APPROVALS & LAUNCHES, JANUARY 2021–MAY 2024
TABLE 880 ABBVIE INC.: DEALS, JANUARY 2021–MAY 2024
TABLE 881 ABBVIE INC.: EXPANSIONS, JANUARY 2021–MAY 2024
TABLE 882 GENMAB A/S: COMPANY OVERVIEW
TABLE 883 GENMAB A/S: PRODUCTS OFFERED
TABLE 884 GENMAB A/S: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
TABLE 885 GENMAB A/S: DEALS, JANUARY 2021–MAY 2024
TABLE 886 GILEAD SCIENCES, INC.: COMPANY OVERVIEW
TABLE 887 GILEAD SCIENCES, INC.: PRODUCTS OFFERED
TABLE 888 GILEAD SCIENCES, INC.: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
TABLE 889 GILEAD SCIENCES, INC.: DEALS, JANUARY 2021–MAY 2024
TABLE 890 GILEAD SCIENCES, INC.: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
TABLE 891 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW
TABLE 892 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED
TABLE 893 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
TABLE 894 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: DEALS,  JANUARY 2021–MAY 2024
TABLE 895 ASTRAZENECA: COMPANY OVERVIEW
TABLE 896 ASTRAZENECA: PRODUCTS OFFERED
TABLE 897 ASTRAZENECA: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
TABLE 898 ASTRAZENECA: DEALS, JANUARY 2021–MAY 2024
TABLE 899 ELI LILLY AND COMPANY: COMPANY OVERVIEW
TABLE 900 ELI LILLY AND COMPANY: PRODUCTS OFFERED
TABLE 901 ELI LILLY AND COMPANY: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
TABLE 902 ELI LILLY AND COMPANY: DEALS, JANUARY 2021–MAY 2024
TABLE 903 ELI LILLY AND COMPANY: EXPANSIONS, JANUARY 2021–MAY 2024
TABLE 904 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
TABLE 905 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
TABLE 906 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT APPROVALS &  LAUNCHES, JANUARY 2021–MAY 2024
TABLE 907 TEVA PHARMACEUTICAL INDUSTRIES LTD.: DEALS, JANUARY 2021–MAY 2024
 
 
LIST OF FIGURES (63 FIGURES)
 
FIGURE 1 PHARMACEUTICAL DRUG DELIVERY MARKET SEGMENTATION
FIGURE 2 RESEARCH DESIGN
FIGURE 3 PRIMARY SOURCES
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY/DEMAND SIDE
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,  DESIGNATION, AND REGION
FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 7 PHARMACEUTICAL DRUG DELIVERY MARKET (REVENUE SHARE ANALYSIS ILLUSTRATION): JOHNSON & JOHNSON
FIGURE 8 PHARMACEUTICAL SALES APPROACH
FIGURE 9 TOP-DOWN APPROACH
FIGURE 10 PHARMACEUTICAL DRUG DELIVERY MARKET: IMPACT OF DROCS ON MARKET GROWTH AND CAGR
FIGURE 11 DATA TRIANGULATION METHODOLOGY
FIGURE 12 PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024 VS. 2029 (USD BILLION)
FIGURE 13 PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION,  2024 VS. 2029 (USD BILLION)
FIGURE 14 PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,  2024 VS. 2029 (USD BILLION)
FIGURE 15 GEOGRAPHICAL SNAPSHOT: PHARMACEUTICAL DRUG DELIVERY MARKET
FIGURE 16 GROWING PREVALENCE OF CHRONIC DISEASES AND INCREASING R&D INVESTMENTS TO DRIVE MARKET GROWTH
FIGURE 17 HOSPITALS ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2023
FIGURE 18 CHINA TO REGISTER HIGHEST REVENUE GROWTH DURING FORECAST PERIOD
FIGURE 19 INJECTABLE DRUG DELIVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 20 BIOPHARMACEUTICAL R&D SPENDING (2020–2023)
FIGURE 21 TOP PHARMA R&D 2023: LARGEST INVESTORS
FIGURE 22 PHARMACEUTICAL DRUG DELIVERY MARKET: VALUE CHAIN ANALYSIS
FIGURE 23 PHARMACEUTICAL DRUG DELIVERY MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 24 PHARMACEUTICAL DRUG DELIVERY MARKET: ECOSYSTEM
FIGURE 25 REVENUE SHIFT IN PHARMACEUTICAL DRUG DELIVERY MARKET
FIGURE 26 GLOBAL NUMBER OF PATENT PUBLICATIONS (JANUARY 2013–MAY 2024)
FIGURE 27 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR PHARMACEUTICAL DRUG DELIVERY PATENTS (JANUARY 2013–MAY 2024)
FIGURE 28 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR CONTROLLED DRUG DELIVERY PATENTS (JANUARY 2013–MAY 2024)
FIGURE 29 PHARMACEUTICAL DRUG DELIVERY MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 30 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS, BY END USER
FIGURE 31 KEY BUYING CRITERIA, BY END USER
FIGURE 32 AVERAGE SELLING PRICE TREND OF MAJOR PHARMACEUTICAL DRUG DELIVERY PRODUCTS, BY KEY PLAYER
FIGURE 33 AVERAGE SELLING PRICE TREND OF MAJOR PHARMACEUTICAL  DRUG DELIVERY PRODUCTS, BY REGION
FIGURE 34 INVESTMENT AND FUNDING SCENARIO FOR PHARMACEUTICAL  DRUG DELIVERY PLAYERS
FIGURE 35 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES FROM  2000 TO 2045 (IN MILLIONS)
FIGURE 36 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET SNAPSHOT
FIGURE 37 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET SNAPSHOT
FIGURE 40 MARKET SHARE ANALYSIS OF KEY PLAYERS IN PHARMACEUTICAL DRUG DELIVERY MARKET SHARE (2023)
FIGURE 41 PHARMACEUTICAL DRUG DELIVERY MARKET:  COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
FIGURE 42 PHARMACEUTICAL DRUG DELIVERY MARKET: COMPANY FOOTPRINT
FIGURE 43 PHARMACEUTICAL DRUG DELIVERY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
FIGURE 44 EV/EBITDA OF KEY VENDORS
FIGURE 45 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR  STOCK BETA OF KEY VENDORS
FIGURE 46 PHARMACEUTICAL DRUG DELIVERY MARKET: BRAND/PRODUCT  COMPARATIVE ANALYSIS
FIGURE 47 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2023)
FIGURE 48 NOVARTIS AG: COMPANY SNAPSHOT (2023)
FIGURE 49 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
FIGURE 50 PFIZER INC.: COMPANY SNAPSHOT (2023)
FIGURE 51 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023)
FIGURE 52 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2023)
FIGURE 53 MERCK & CO., INC.: COMPANY SNAPSHOT (2023)
FIGURE 54 SANOFI: COMPANY SNAPSHOT (2023)
FIGURE 55 BAYER AG: COMPANY SNAPSHOT (2023)
FIGURE 56 AMGEN, INC.: COMPANY SNAPSHOT (2023)
FIGURE 57 ABBVIE, INC.: COMPANY SNAPSHOT (2023)
FIGURE 58 GENMAB A/S: COMPANY SNAPSHOT (2023)
FIGURE 59 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2023)
FIGURE 60 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2023)
FIGURE 61 ASTRAZENECA: COMPANY SNAPSHOT (2023)
FIGURE 62 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2023)
FIGURE 63 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2023)
 

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, fundamental market dynamics, and key player strategies.

Secondary Research

The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, SEC filings of companies and publications from government sources [such as National Institutes of Health (NIH), US FDA, US Census Bureau, World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), European Federation of Pharmaceutical Industries and Associations (EFPIA), American Journal of Drug Delivery and Therapeutics, Center for Drug Delivery and Nanomedicine (CDDN) and Parenteral Drug Association (PDA) were referred to identify and collect information for the global pharmaceutical drug delivery  market study. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the pharmaceutical drug delivery  market. The primary sources from the demand side include hospitals, ambulatory surgical centers/clinics, home care setting, diagnostic centers among others. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.

A breakdown of the primary respondents is provided below:

Pharmaceutical Drug Delivery Market Size, and Share

*C-level primaries include CEOs, CFOs, COOs, and VPs.

*Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

Note: Companies are classified into tiers based on their total revenue. As of 2022, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = <USD 1.00 billion.

Source: MarketsandMarkets Analysis

To know about the assumptions considered for the study, download the pdf brochure

Market Estimation Methodology

For the global market value, annual revenues were calculated based on the revenue mapping of major product manufacturers and OEMs active in the global pharmaceutical drug delivery market. All the major product manufacturers were identified at the global and/or country/regional level. Revenue mapping for the respective business segments/sub-segments was done for the major players (who contribute at least 45-48% of the market share at the global level). Also, the global pharmaceutical drug delivery  market was split into various segments and sub-segments based on:

  • List of major players operating in the pharmaceutical drug delivery  products market at the regional and/or country level
  • Product mapping of various pharmaceutical drug delivery  manufacturers at the regional and/or country level
  • Mapping of annual revenue generated by listed major players from pharmaceutical drug delivery (or the nearest reported business unit/product category)
  • Revenue mapping of major players to cover at least 45% of the global market share as of 2023
  • Extrapolation of the revenue mapping of the listed major players to derive the global market value of the respective segments/subsegments
  • Summation of the market value of all segments/subsegments to arrive at the global point-of-care  diagnostics market

The above-mentioned data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.

Market Size Estimation: Pharmaceutical Drug Delivery   Market Based On Revenue Mapping Methodology

Revenue Share Analysis-Bottom Up Approach

Pharmaceutical Drug Delivery Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Top Down Approach

Pharmaceutical Drug Delivery Market Size, and Share

Data Triangulation

After arriving at the overall size of the global Pharmaceutical drug delivery market through the above-mentioned methodology, this market was split into several segments and subsegments. The data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact market value data for the key segments and subsegments. The extrapolated market data was triangulated by studying various macro indicators and regional trends from both demand- and supply-side participants.

Market Definition

Drug delivery is a method or process of administration of a pharmaceutical drug to safely attain its desired therapeutic effect. Advancements in drug delivery offer several benefits, such as ease of use, convenience, and patient compliance. Drug delivery technologies are used for the targeted delivery and/or controlled release of therapeutic agents.

Key Market Stakeholders

  • Pharmaceutical manufacturing companies
  • Original equipment manufacturing companies
  • Suppliers and distributors of pharmaceutical products and medical devices
  • Healthcare service providers
  • Teaching hospitals and academic medical centers
  • Health insurance players
  • Government bodies/municipal corporations
  • Regulatory bodies
  • Medical research institutes
  • Business research and consulting service providers
  • Venture capitalists
  • Market research and consulting firms

Report Objectives

  • To define, describe, and forecast the global pharmaceutical drug delivery  market on the basis of pharmaceutical drug delivery  product, route of administration, application, facility of use, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the overall market
  • To analyze the opportunities in the market for key stakeholders and provide details of the competitive landscape for major market leaders
  • To forecast the size of the market segments with respect to five main regions, namely, North America (the US and Canada), Europe (Germany, the UK, France, Italy, Spain, and Rest of Europe), Asia Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East & Africa
  • To profile the key market players and comprehensively analyze their market shares and core competencies2
  • To track and analyze competitive developments such as mergers and acquisitions, new product developments, partnerships, agreements, collaborations, and expansions in the global pharmaceutical drug delivery   market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the global pharmaceutical drug delivery  market report.

Product Analysis

  • Product Matrix, which gives a detailed comparison of the product portfolios of the top five global players.

Company Information

  • Detailed analysis and profiling of additional market players (up to 5 players)

Geographic Analysis

  • Further breakdown of the Rest of Europe pharmaceutical drug delivery  market into Belgium, Austria, the Netherlands, Switzerland, Austria, Finland, Sweden, Poland, and Portugal, among other
  • Further breakdown of the Rest of Asia Pacific pharmaceutical drug delivery   market into New Zealand, Vietnam, Philippines, Singapore, Malaysia, Thailand, and Indonesia, among other countries
  •  Further breakdown of the Rest of Latin America pharmaceutical drug delivery  market into Argentina, and Colombia, among other countries.
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 3871
Published ON
Sep, 2024
REQUEST FREE SAMPLE REPORT
Choose License Type
BUY NOW
Inquire Before Buying
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Pharmaceutical Drug Delivery Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
Latest News
READ MORE
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status
Website Feedback